Declared 27 percent and the harm side: what reviews link to higher potency

• How much evidence. 4 works from 2021 to 2025, all listed in the table below along with the model.
• What has not been shown. It has not been shown that a higher declared percentage on the label means stronger or better therapeutic action. The evidence material on the potency of the raw material concerns almost exclusively adverse effects and non-medical use, not effectiveness.
• What you won’t find here. Dosage recommendations or strain indications. The choice is made by the attending physician, and cannabis flower is a raw material dispensed only by prescription.
• How to read this. The result of a study on rodents or in cell culture does not directly transfer to a patient taking the flower, and the column with the model indicates what the work was actually about.

What does the declared 27 percent on the flower label mean?

It means the sum of THC, that is, the content of tetrahydrocannabinol along with its acid form converted to the active form. In freshly dried flowers, almost the entire load is still in acid form, so the number on the label describes the potential of the raw material after heating, not the portion that the patient absorbs during a single treatment.

The division into acid and active form is not a laboratory detail. Tetrahydrocannabinolic acid weighs more than the molecule that forms from it after the release of carbon dioxide, so when converting, it is multiplied by a factor of 0.877. The monograph Cannabis flos in the European Pharmacopoeia describes precisely the sum of THC, not just the neutral form, and this is how the declaration on the packaging of pharmaceutical raw material is read. Heating only partially converts the acid to the active form, and part of the load is lost with vapor and residue, so 27 from the label is not the amount that enters the bloodstream.

The declaration has an allowable deviation, so one number actually describes a range, not a point. Separately stands the question of how much of this declaration is confirmed by the measurement of a specific batch, because the study is performed on a sample, not on the entire package. The overlap of adjacent potency ranges is discussed on the page about eighteen percent, and the distance between the declaration and the measurement is discussed on the page about twenty percent. This page is not a product listing: the assortment along with availability leads to a compilation of currently available medical marijuana strains.

How is the potency of the flower matched to a specific patient?

This is determined by the attending physician, not the number on the package. The practice described in the literature involves starting with small amounts and gradually reaching the dose at which symptoms subside, while adverse effects remain manageable; the potency of the raw material is just one of the variables in this calculation.

Higher potency changes not so much the goal as the jump between successive steps. The same volume of material carries more active substance at 27 percent than at twelve, so a single inhalation corresponds to a larger portion and the margin of error becomes narrower. A person taking the raw material for a long time usually tolerates stronger material better than a beginner, as tolerance builds with exposure. However, this same tolerance can be a reason for reaching for increasingly stronger flower, and this is an area where reviews see a link to cannabis dependence.

This page does not provide portion calculations, as cannabis flower is a pharmaceutical raw material dispensed by prescription in the Rpw category, and the method of administration is determined by the attending physician. The mechanics of reaching a portion is discussed on the page about twenty-two percent. Here, one distinction is sufficient: potency describes the raw material, while portion describes treatment, and one cannot be converted to the other without knowledge of the route of administration and previous exposure.

Does the declared 27 percent change the onset and duration of action?

No. The declared potency determines how much substance is delivered in a single portion of material, not the rate at which the body absorbs and eliminates it. The onset and duration of the episode depend on the route of administration, so comparing potencies makes sense only when the route of administration is the same.

The route of administration determines the course more than the strain itself. After vaporization, the substance passes from the lungs to the blood almost immediately, so the first sensations appear after a few minutes, the intensity increases for another ten to thirty minutes, and the whole effect lasts for two to four hours. After ingestion, the raw material first passes through the intestine and liver, so the first sensations are awaited from half an hour to two, and the episode lasts six, sometimes eight hours. This is where the most common mistake in oral administration comes from: anyone who thinks after thirty minutes that nothing is happening and adjusts the dose will receive both doses at once. The above ranges describe the route of administration, not the strain; pharmacokinetic studies for a single cultivar have not been published.

With stronger raw material, the slope of the same curve changes, not its shape. The same inhalation delivers more substance, so the peak occurs higher, not earlier, and it is this that determines whether the episode will be perceived as too intense. In oral administration, the difference is more serious, as the mistake described above costs more the stronger the material that went into the preparation. Thus, the declared percentage does not shorten the wait nor lengthen the episode; it only shifts the height of the peak.

What is known about the relationship between raw material potency and effect, and what is not known?

What is mainly known is about the harms. The evidence material concerning potency itself primarily describes psychosis and cannabis dependence and comes mostly from observational studies, which show correlation, not causation. Almost nothing is known about the relationship between the declared percentage and the effectiveness of treatment.

What adverse effects are associated with higher potency raw material?

The same as with weaker raw material, only more frequent with comparable amounts of material. Two phenomena described directly with higher potency stand apart: psychosis or schizophrenia and cannabis dependence. Both come from observational works and both speak of correlation, not proven causation.

Reports of adverse effects are collected for medicinal products with a batch number, not for the strain name, so the following concerns cannabis flower as a group of raw materials. The most common are dry mouth, red eyes, and increased heart rate. Dizziness upon rapid standing, daytime drowsiness, and temporary worsening of short-term memory are less frequently reported, as well as anxiety that increases with dosage. A separate issue is medications taken concurrently, especially sedatives and those affecting coagulation: their assessment requires knowledge of the entire list of preparations, not just the description of the plant. We do not provide numerical frequencies for these symptoms, as public compilations for cannabis flower in Poland do not separate them by individual products.

In the branch assessing therapeutic use, the picture was different: nearly half of the works found benefit for anxiety (47 percent) and for depression (48 percent), and some of them simultaneously described unfavorable associations (24 and 30 percent). Thus, both branches say different things.

The percentage of works reporting a link is not the risk for an individual nor a measure of the strength of that link. An observational study compares groups differing not only in raw material potency but also in age, frequency of use, and reason for using cannabis, so the reverse direction of dependence remains open: a more severe course of disorder may lead to stronger material, not the other way around.

Frequently asked questions

Does flower with a declaration of 27 percent work stronger than flower with a lower declaration?

With the same amount of material, it delivers more active substance, which is not the same as stronger therapeutic action. Comparisons of two pharmaceutical flowers differing only in declared content have not been published, so the difference in therapeutic effect remains unknown.

Does a higher percentage on the label mean better therapeutic action?

It has not been shown that a higher declared percentage on the label means stronger or better therapeutic action. The evidence material on the potency of the raw material concerns almost exclusively adverse effects and non-medical use, not effectiveness, and works on therapeutic use are few and yield mixed results. The authors of both of the latest reviews rated the certainty of evidence as very low. There is also no study that compared two pharmaceutical flowers differing only in declared content.

Is 27 percent a lot?

In terms used in the literature, this number falls within the range of twenty to thirty percent, which is in the upper part of the range described for flower. Above that are kief, resin, and concentrates, which this page does not address.

Does the declared 27 percent equal measured 27 percent?

No. The declaration has an allowable deviation, and the measurement is performed on a sample taken from the batch. Thus, the label with one number describes a range, not the value read from a specific package.

Does higher potency raw material have different adverse effects?

The reported symptoms are the same, differing only in frequency with comparable amounts of material. Isolated for higher potency are psychosis or schizophrenia and cannabis dependence, described in observational studies as co-occurrence.

Who decides on the potency of raw material in treatment?

The attending physician, on the prescription in the Rpw category. The informational page does not replace either indication or the choice of form and method of administration.

Where to check which strains of this potency are available?

In the compilation of currently available medical marijuana strains, which is maintained by the hub of this collection of pages. This page describes only the number on the label and the state of evidence, not the assortment.

The material is informational and does not replace medical advice. Editorial: ubucha.